8-K: Invivyd's COVID-19 Treatment Expansion Request Denied by FDA; Existing Pre-Exposure Prophylaxis Authorization Remains

Invivyd's request to expand the emergency use authorization of PEMGARDA for COVID-19 treatment in immunocompromised patients was declined by the FDA, while the existing authorization for pre-exposure prophylaxis remains in effect.

Summary

• Invivyd announced that the FDA declined its request to expand the emergency use authorization (EUA) for PEMGARDA (pemivibart) to include treatment of mild-to-moderate COVID-19 in immunocompromised individuals with no alternative therapeutic options.
• The existing EUA for PEMGARDA for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients remains in effect.
• The FDA's decision was based on the belief that COVID-19 treatment immunobridging analyses for monoclonal antibodies must demonstrate superior, rather than equivalent, antiviral activity compared to previously authorized mAbs.
• Invivyd's submission demonstrated comparable antiviral activity between pemivibart and adintrevimab, and predicted clinical efficacy in line with prior authorized mAb therapeutics.
• Invivyd plans to continue working with the FDA to advance PEMGARDA as a COVID-19 treatment and will also rapidly advance VYD2311 in collaboration with the FDA.
• The company intends to share detailed data and regulatory correspondence regarding pemivibart, VYD2311, and immunobridging of COVID-19 antibodies.
• The COVID-19 treatment opportunity for pemivibart was not included in the company's existing financial guidance.
• Invivyd also announced that it has regained compliance with the Nasdaq minimum bid price requirement.

Sentiment

Score: 4

Explanation: The sentiment is somewhat negative due to the FDA's rejection of the EUA expansion, but there's a glimmer of hope with the continued EUA for pre-exposure prophylaxis and the ongoing development of VYD2311. The management's comments express disappointment, further contributing to the negative sentiment.

Positives

• Invivyd has regained compliance with the Nasdaq minimum bid price requirement, ensuring continued listing on The Nasdaq Global Market.
• The existing EUA for PEMGARDA for pre-exposure prophylaxis in certain immunocompromised patients remains in effect, providing a preventative option.
• Invivyd is actively pursuing the development of VYD2311, a novel monoclonal antibody candidate for COVID-19, with plans to advance it in collaboration with the FDA.

Negatives

• The FDA declined Invivyd's request to expand the EUA for PEMGARDA to include COVID-19 treatment for immunocompromised patients, limiting its potential use.
• The FDA's decision was based on a requirement for superior antiviral activity compared to previous mAbs, which pemivibart did not demonstrate in immunobridging analyses.
• The COVID-19 treatment opportunity for pemivibart was not contemplated in existing financial guidance, suggesting a potential impact on future revenue projections.

Risks

• The outcome of Invivyd's efforts with the FDA to advance PEMGARDA as a COVID-19 treatment and VYD2311 is uncertain.
• The EUA granted by the FDA for PEMGARDA for PrEP could be revised or revoked.
• The company faces risks related to the regulatory authorization or approval process for its product candidates.
• Unexpected safety or efficacy data observed during preclinical studies or clinical trials could impact the development of product candidates.
• The company's ability to maintain and expand sales, marketing, and distribution capabilities to successfully commercialize PEMGARDA is a risk factor.
• Changes in expected or existing competition could impact the company's market position.
• The company's ability to continue as a going concern and whether it has adequate funding to meet future operating expenses and capital expenditure requirements are risks.

Future Outlook

Invivyd plans to continue working with the FDA to advance PEMGARDA as a COVID-19 treatment for certain immunocompromised patients and will also rapidly advance VYD2311 in collaboration with the FDA. The company intends to share detailed data and regulatory correspondence regarding pemivibart, VYD2311, and immunobridging of COVID-19 antibodies.

Management Comments

• 'This is a sad day for patients in need. Immunocompromised people who cannot access standard of care are once again left with no option for COVID-19 treatment,' commented Mark Wingertzahn, Invivyd's Senior Vice President of Clinical Development.
• Dr. Alfred H. Kim, MD, PhD, Associate Professor of Medicine, Associate Professor of Pathology and Immunology, Washington University School of Medicine, commented, 'We need tools like PEMGARDA immediately to lessen the ongoing, unacceptable burden of COVID-19 death and hospitalization.'

Industry Context

The FDA's decision reflects a cautious approach to authorizing new COVID-19 treatments, particularly in light of evolving variants and the availability of existing therapies. The emphasis on superior antiviral activity compared to previous mAbs suggests a higher bar for new entrants in the treatment landscape. This decision could impact other companies developing similar therapies and highlights the challenges of navigating the regulatory pathway for COVID-19 treatments.

Comparison to Industry Standards

• The FDA's requirement for superior antiviral activity in immunobridging analyses sets a high standard compared to previous authorizations, where equivalent activity was sometimes sufficient.
• The document mentions adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA, suggesting that Invivyd aimed to demonstrate comparable efficacy to these established treatments.
• The comparison to PAXLOVID highlights the need for alternative treatment options for patients who are contraindicated, unable to access, or for whom PAXLOVID is clinically inappropriate.

Stakeholder Impact

• Immunocompromised patients who could have benefited from PEMGARDA as a treatment option are negatively impacted by the FDA's decision.
• Healthcare providers are limited in their treatment options for COVID-19 in immunocompromised patients.
• Invivyd's shareholders may experience a negative impact due to the limited potential of PEMGARDA and the uncertainty surrounding future revenue projections.

Next Steps

• Invivyd plans to continue efforts with the FDA to advance PEMGARDA as a COVID-19 treatment.
• Invivyd plans to rapidly advance VYD2311 in collaboration with the FDA.
• Invivyd plans to share detailed data and regulatory correspondence regarding pemivibart, VYD2311, and immunobridging of COVID-19 antibodies.

Key Dates

Keywords

PEMGARDA, COVID-19, FDA, Emergency Use Authorization, Immunocompromised, VYD2311, Monoclonal Antibody, Pre-Exposure Prophylaxis, Treatment, Invivyd